Neurol. praxi. 2008;9(6):356-360

TREATMENT OF MENSTRUAL AND PERIMENSTRUAL MIGRAINE

MUDr. Jiří Mastík
Neurologická klinika LF MU a FN u sv. Anny, Brno

Menstrual migraine is a subtype of migraine without aura. Pure menstrual migraine (PMM) which occurs during menstruation, and menstrually-related migraine (MRM) which can also occur outside menstruation are distinguished. In pathophysiology, a decrease in the oestrogen level by the end of the luteal phase of the cycle as well as an increase in prostaglandin within the first 48 hours of menstruation are thought to play the main role. Acute treatment and prophylaxis of MRM do not differ from the routine treatment. Prophylactic treatment of PMM involves intermittent prophylaxis with nonsteroid anti-inflammatory drugs or frovatriptan, hormonal prophylaxis involves the use of steadily high

or low levels of oestrogens.

Keywords: Key words: migraine, menstruation, oestrogens, triptans, frovatriptan.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mastík J. TREATMENT OF MENSTRUAL AND PERIMENSTRUAL MIGRAINE. Neurol. praxi. 2008;9(6):356-360.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. de Lignieres B, et al. Prevention of menstrual migraine by percutaneous oestradiol. BMJ 1986; 293: 1450. Go to original source... Go to PubMed...
    2. Dennerstein L, et al. Menstrual migraine: a double-blind trial of percutaneous oestradiol. Gynaecol Endocrinol 1988; 2: 113-120. Go to original source... Go to PubMed...
    3. Granella F, et al. Treatment of menstrual migraine. Cephalalgia 1997; 20(Suppl 17): 35-38. Go to original source... Go to PubMed...
    4. Headache Classification Subcommittaee of the International Headache Society: The International Classification and diagnostic criteria of headache disorders. 2nd edition. Cephalalgia. 2004; 24(1): 160 s.
    5. Herzog AG. Continuous bromocriptine therapy in menstrual migraine. Neurology 1997; 48: 101-102. Go to original source... Go to PubMed...
    6. Kotas R, et al. Migréna. Patofyziologie a léčba. Praha: Maxdorf, 2001; 195 s.
    7. Lichten EM, et al. Efficacy of Danazol in the control of hormonal migraine. J Reprod Med 1991; 36: 419-424. Go to PubMed...
    8. MacGregor EA. Menstrual migraine: towards a definition. Cephalalgia 1996; 16: 11-21. Go to original source... Go to PubMed...
    9. MacGregor A. Migraine in women. Martin Duniz: London 1999; 90 s. Go to original source...
    10. MacGregor EA, Tobin J, Hutchinson J. An interim analysis of the safety and tolerability of frovatriptan for the prevention of menstrually related migraine headaches. Headache 2005; 45: 822.
    11. Marková J. Bolesti hlavy. Praha: Triton, 2004; 71 s.
    12. Markova J, et al. Frovatriptan for intermitent prevention of menstrual migraine. Abstract in Europ J of Neurol 2008; 15(Suppl.3): 335.
    13. Mastík J. Migréna. Praha: Maxdorf, 2007; 104 s.
    14. O Brien PS. Helping woman with the premenstrual syndrome. BMJ 1993; 307: 1471-1475. Go to original source... Go to PubMed...
    15. O Dea JPK, Davis EH. Tamoxifen in the treatment of menstrual migraine. Neurology 1990; 40: 1470-1471. Go to original source... Go to PubMed...
    16. Silberstein SD, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004; 63: 261-269. Go to original source... Go to PubMed...
    17. Steiner TJ, MacGregor A, Davies PG. Guidelines in the Diagnosis and Management of Migraine. London: Beta edition, 1998; 1-24.
    18. Waberžinek G. Migréna - diagnostika a léčba. Praha: Triton, 2003; 158 s.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.